Cargando…
CXCR4 in Waldenström’s Macroglobulinema: chances and challenges
It is one of the major aims in cancer research to improve our understanding of the underlying mechanisms which initiate and maintain tumor growth and to translate these findings into novel clinical diagnostic and therapeutic concepts with the ultimate goal to improve patient care. One of the greater...
Autores principales: | Kaiser, Lisa Marie, Hunter, Zachary R., Treon, Steven P., Buske, Christian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862063/ https://www.ncbi.nlm.nih.gov/pubmed/33273682 http://dx.doi.org/10.1038/s41375-020-01102-3 |
Ejemplares similares
-
Targeting of CXCR4 by the Naturally Occurring CXCR4 Antagonist EPI-X4 in Waldenström’s Macroglobulinemia
por: Kaiser, Lisa Marie, et al.
Publicado: (2021) -
Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia
por: Castillo, Jorge J., et al.
Publicado: (2023) -
Genomic landscape of Waldenström's macroglobulinemia
por: Treon, Steven P., et al.
Publicado: (2019) -
Aberrant CXCR4 Signaling at Crossroad of WHIM Syndrome and Waldenstrom’s Macroglobulinemia
por: Milanesi, Samantha, et al.
Publicado: (2020) -
Managing Waldenström’s macroglobulinemia with BTK inhibitors
por: Buske, Christian, et al.
Publicado: (2022)